Merck & Company Inc (MRK)
U.S. FDA Approves Merck’s ENFLONSIA™(clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season
U.S. FDA Approves Merck’s ENFLONSIA™(clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season
There are no comments here yet...